Sirtris Pharmaceuticals To Present at 6th Annual Metabolic Diseases Drug Discovery and Development World Summit, July 17, 2007
12 July 2007 - 10:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced today that it will be
presenting at the 6th Annual Metabolic Diseases Drug Discovery and
Development World Summit in San Diego, California. Jill Milne,
Ph.D., Senior Director of Biology at Sirtris, will deliver a
keynote address �SIRT1 Activation: A Novel Mechanism for Treating
Type 2 Diabetes.� Her presentation is scheduled to be delivered at
8:45 am PST on Tuesday, July 17, 2007. About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that control the aging
process. The company's headquarters are in Cambridge,
Massachusetts. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 concerning Sirtris Pharmaceuticals, its product
candidates, and those candidates' clinical potential. These
forward-looking statements about future expectations, plans and
prospects of Sirtris Pharmaceuticals involve significant risks,
uncertainties and assumptions, including risks related to the lack
of results that would provide a basis for predicting whether any of
the Company�s product candidates will be safe or effective, or
receive regulatory approval, the Company's potential inability to
initiate and complete preclinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the�Company to gain market acceptance of the Company's
product candidates, and those other risks factors�that can be found
in the�Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles